AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CLARITY PHARMACEUTICALS LTD

2.430

+0.000

Volume:1.96M

Turnover:4.76M

Market Cap:780.88M

PE:-15.01

High:2.530

Open:2.460

Low:2.370

Close:2.430

Loading ...

Overview Company News Filings

Clarity Pharmaceuticals signs copper-64 isotope supply deal for use in prostate cancer trials

Why Appen, Clarity, Qantas, and Resolute shares are pushing higher today

Clarity Pharmaceuticals Completes Dose Escalation Phase of SECuRE Trial; Shares Rise 4%

MT Newswires Live

Clarity Pharmaceuticals Signs Copper-64 Isotope Supply Agreement with University of Queensland

MT Newswires Live

BUZZ-Clarity Pharmaceuticals gains on supply agreement with University of Queensland

Guess which ASX 200 biotech stock is jumping 7% on big news

Clarity Bull Pushes Out Timing of U.S. Reimbursement Approval -- Market Talk

BUZZ-Australia's Clarity Pharmaceuticals hits 10-month low on bigger HY loss

Why Aurizon, Brainchip, Clarity, and Domino's shares tumbling today

Clarity Pharmaceuticals Fiscal H1 Loss Widens

MT Newswires Live

BRIEF-Clarity Pharmaceuticals Posts HY Loss From Ordinary Activities After Tax A$23.582 Million

Clarity Pharmaceuticals Ltd - Hy Loss From Ordinary Activities After Tax a$23.582 Million

THOMSON REUTERS

BRIEF-Clarity Receives Us FDA Fast Track Designation For The Treatment Of Metastatic Castration-Resistant Prostate Cancer Patients With Cu-67 Sar-Bispsma

Clarity Receives US FDA Fast Track Designation for the Treatment of Metastatic Castration-Resistant Prostate Cancer Patients With Cu-67 SAR-Bispsma

THOMSON REUTERS

Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA

2 ASX 200 pharmaceutical shares surging on big US news

Clarity Pharmaceuticals Secures US FDA Fast Track Designation for Prostate Cancer Drug Candidate; Shares Up 3%

MT Newswires Live

Another win for Clarity at FDA as imaging agent fast-tracked for complex prostate cancer

The Market Herald

BRIEF-Clarity Pharmaceuticals Gets US FDA Fast Track Designation

Clarity Pharmaceuticals - Gets US FDA Fast Track Designation for Treatment of Metastatic Castration-Resistant Prostate Cancer Patients

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CU6.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":2.43,"timestamp":1746771120000,"preClose":2.43,"halted":0,"volume":1955204,"delay":0,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":225167378,"shares":321351612,"eps":-0.161928,"marketStatus":"Market Closed","change":0,"latestTime":"05-09 16:12:00 AEST","open":2.46,"high":2.53,"low":2.37,"amount":4757121,"amplitude":0.065844,"askPrice":2.44,"askSize":10090,"bidPrice":2.4,"bidSize":8333,"shortable":3,"etf":0,"ttmEps":-0.161928,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1747008000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":2.43,"openAndCloseTimeList":[[1746748800000,1746770400000]],"volumeRatio":0.5218019466648234,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":225167378,"roa":"-36.11%","roe":"-53.99%","lyrEps":-0.154944,"volumeRatio":0.5218019466648234,"shares":321351612,"dividePrice":0,"high":2.53,"amplitude":0.065844,"preClose":2.43,"low":2.37,"week52Low":1.43,"pbRate":"6.13","psRate":"72.46","week52High":8.975,"institutionHeld":0,"latestPrice":2.43,"committee":-0.09537,"eps":-0.161928,"divideRate":0,"volume":1955204,"delay":0,"ttmEps":-0.161928,"open":2.46,"prevYearClose":4.17,"prevWeekClose":2.6,"prevMonthClose":2.2,"prevQuarterClose":2.11,"fiveDayClose":2.6,"twentyDayClose":1.54,"sixtyDayClose":3.46},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517635952","title":"Clarity Pharmaceuticals signs copper-64 isotope supply deal for use in prostate cancer trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2517635952","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517635952?lang=en_us&edition=fundamental","pubTime":"2025-03-05 12:33","pubTimestamp":1741149193,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  has signed a deal with the Australian Institute for Bioengineering and Nanotechnology , located within the University of Queensland, for the supply of the copper-64  isotope used in the manufacture of diagnostic 64Cu-SAR-bisPSMA.Clarity will use the isotope to support the Phase III Clarify and Amplify registrational trials, an ongoing Co-PSMA  investigator-initiated trial and the SECuRE theranostic trial, all based in Australia.It will also benefit the advancement of Clarity’s pre-clinical schedule, including the SAR-bisFAP and SAR-trastuzumab theranostic programs.Clarity executive chair Dr Alan Taylor said the supply agreement would ultimately benefit Australian patients and their treating clinicians.“This agreement builds on years of close ties between Clarity and the Australian scientific and clinical communities and reflects our strong focus on continued partnership and synergies that can be derived from these important collaborations,” he said.The AIBN hou","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/03/Clarity-Pharmaceuticals-ASX-CU6-Cu-64-Supply-Agreement-University-Queensland.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/03/Clarity-Pharmaceuticals-ASX-CU6-Cu-64-Supply-Agreement-University-Queensland.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/clarity-pharmaceuticals-copper-64-isotope-supply-prostate-cancer-trials/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7096","XKO.AU","XAO.AU","CU6.AU","XJO.AU"],"gpt_icon":0},{"id":"2517195715","title":"Why Appen, Clarity, Qantas, and Resolute shares are pushing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2517195715","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517195715?lang=en_us&edition=fundamental","pubTime":"2025-03-05 10:25","pubTimestamp":1741141539,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is having another tough session on Wednesday. In afternoon trade, the benchmark index is down a disappointing 1.2% to 8,099.7 points. Four ASX shares that have not let ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/05/why-appen-clarity-qantas-and-resolute-shares-are-pushing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4080","BK7503","BK7030","SRC","APX.AU","CU6.AU","BK7096","BK4231","BK7104","BK7506","RSG.AU","XJO.AU","BK7061","QAN.AU"],"gpt_icon":1},{"id":"2517937753","title":"Clarity Pharmaceuticals Completes Dose Escalation Phase of SECuRE Trial; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517937753","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517937753?lang=en_us&edition=fundamental","pubTime":"2025-03-05 10:14","pubTimestamp":1741140884,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  completed the dose escalation phase of its SECuRE trial, according to a Wednesday Australian bourse filing.The safety review committee recommended that it proceed to the cohort expansion phase of the study at eight gigabecquerel dose level and increase the number of cycles from four to up to six.The SECuRE trial assesses the safety and efficacy of the drug in the treatment of patients with metastatic castrate-resistant prostate cancer.It said that across all cohorts of the dose escalation phase, 68% of the participants showed a reduction in prostate-specific antigen, despite 77% of the participants only receiving a single dose of copper-67-SAR-bisPSMA. It also showed a favorable safety profile across all cohorts.The SECuRE trial protocol was amended to administer copper-67-SAR-bisPSMA to participants at earlier stages of the disease, in a pre-chemotherapy setting, incorporating an increase in the number of participants from 14 to 24, with a subset expected to r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2517993179","title":"Clarity Pharmaceuticals Signs Copper-64 Isotope Supply Agreement with University of Queensland","url":"https://stock-news.laohu8.com/highlight/detail?id=2517993179","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517993179?lang=en_us&edition=fundamental","pubTime":"2025-03-05 09:31","pubTimestamp":1741138281,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  signed a copper-64 isotope supply agreement with the University of Queensland's Australian Institute for Biotechnology and Nanotechnology, according to a Wednesday Australian bourse filing.The supply agreement will support the firm's clinical trials with copper-64 SAR-bisPSMA imaging agent in Australia for prostate cancer patients. It will also support the rollout of two theranostic preclinical programs, SAR-bisFAP and SAR-trastuzumab.It will expand the manufacturing capability of the agent for the phase three CLARIFY and AMPLIFY registrational trials in Australia, an ongoing investigator-initiated trial, as well as the Co-PSMA and SECuRE theranostic trials.The firm's shares rose 2% in recent trading on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","BK7096","XAO.AU","CU6.AU","XKO.AU"],"gpt_icon":0},{"id":"2517338189","title":"BUZZ-Clarity Pharmaceuticals gains on supply agreement with University of Queensland","url":"https://stock-news.laohu8.com/highlight/detail?id=2517338189","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517338189?lang=en_us&edition=fundamental","pubTime":"2025-03-05 07:53","pubTimestamp":1741132438,"startTime":"0","endTime":"0","summary":"BUZZ-Clarity Pharmaceuticals gains on supply agreement with University of Queensland** Shares of Australia's Clarity Pharmaceuticals CU6.AX rise as much as 7.1% to A$3.180, their biggest intraday pct ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN2BO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2517954233","title":"Guess which ASX 200 biotech stock is jumping 7% on big news","url":"https://stock-news.laohu8.com/highlight/detail?id=2517954233","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517954233?lang=en_us&edition=fundamental","pubTime":"2025-03-05 07:30","pubTimestamp":1741131012,"startTime":"0","endTime":"0","summary":"The Clarity Pharmaceuticals Ltd  share price is avoiding the market weakness on Wednesday. In morning trade, the ASX 200 biotech stock is up 7% to $3.18. Why is this ASX 200 biotech stock jumping?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/05/guess-which-asx-200-biotech-stock-is-jumping-7-on-big-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XKO.AU","BK4080","SRC","XAO.AU","BK7096","BK4231","XJO.AU","CU6.AU"],"gpt_icon":0},{"id":"2516770664","title":"Clarity Bull Pushes Out Timing of U.S. Reimbursement Approval -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2516770664","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516770664?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:37","pubTimestamp":1741041420,"startTime":"0","endTime":"0","summary":"Copyright (c) 2025 Dow Jones & Company, Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2516443575","title":"BUZZ-Australia's Clarity Pharmaceuticals hits 10-month low on bigger HY loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2516443575","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516443575?lang=en_us&edition=fundamental","pubTime":"2025-03-03 11:48","pubTimestamp":1740973700,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Clarity Pharmaceuticals hits 10-month low on bigger HY loss** Shares of Clarity Pharmaceuticals CU6.AX down 15% to A$3.025, top losers on the S&P/ASX 200 .AXJO benchmark index** Stock","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL3N3PM06U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2516578881","title":"Why Aurizon, Brainchip, Clarity, and Domino's shares tumbling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2516578881","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516578881?lang=en_us&edition=fundamental","pubTime":"2025-03-03 09:45","pubTimestamp":1740966356,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index (ASX: XJO) has followed Wall Street's lead and is pushing higher. At the time of writing, the benchmark index is up 0.3% to 8,197.4 points. Four ASX shares tha","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/03/why-aurizon-brainchip-clarity-and-dominos-shares-tumbling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7137","BK7140","CU6.AU","DMP.AU","BK7096","BRN.AU","AZJ.AU","BK7016","XJO.AU"],"gpt_icon":0},{"id":"2514620318","title":"Clarity Pharmaceuticals Fiscal H1 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2514620318","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514620318?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:04","pubTimestamp":1740726276,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  reported Friday that its loss per diluted share in the fiscal first half widened to AU$0.074, compared to a loss of AU$0.066 per diluted share a year earlier.Analysts polled by Visible Alpha were expecting a loss of AU$0.08 per share.The company said it did not derive any revenue, as it does not have any commercial products.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2514983396","title":"BRIEF-Clarity Pharmaceuticals Posts HY Loss From Ordinary Activities After Tax A$23.582 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514983396","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514983396?lang=en_us&edition=fundamental","pubTime":"2025-02-28 12:58","pubTimestamp":1740718693,"startTime":"0","endTime":"0","summary":"BRIEF-Clarity Pharmaceuticals Posts HY Loss From Ordinary Activities After Tax A$23.582 MillionFeb 28 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX:HY LOSS FROM ORDINARY ACTIVITIES AFTER TAX A$23.582 MILLIONFurther company coverage: CU6.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2514965283","title":"Clarity Pharmaceuticals Ltd - Hy Loss From Ordinary Activities After Tax a$23.582 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514965283","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514965283?lang=en_us&edition=fundamental","pubTime":"2025-02-28 12:53","pubTimestamp":1740718424,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2512485231","title":"BRIEF-Clarity Receives Us FDA Fast Track Designation For The Treatment Of Metastatic Castration-Resistant Prostate Cancer Patients With Cu-67 Sar-Bispsma","url":"https://stock-news.laohu8.com/highlight/detail?id=2512485231","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512485231?lang=en_us&edition=fundamental","pubTime":"2025-02-19 23:12","pubTimestamp":1739977920,"startTime":"0","endTime":"0","summary":"BRIEF-Clarity Receives Us FDA Fast Track Designation For The Treatment Of Metastatic Castration-Resistant Prostate Cancer Patients With Cu-67 Sar-BispsmaFeb 19 (Reuters) - Clarity Pharmaceuticals Ltd ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUABJTKYC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":1},{"id":"2512100352","title":"Clarity Receives US FDA Fast Track Designation for the Treatment of Metastatic Castration-Resistant Prostate Cancer Patients With Cu-67 SAR-Bispsma","url":"https://stock-news.laohu8.com/highlight/detail?id=2512100352","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512100352?lang=en_us&edition=fundamental","pubTime":"2025-02-19 22:09","pubTimestamp":1739974143,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUABJTKYC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2512100248","title":"Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2512100248","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512100248?lang=en_us&edition=fundamental","pubTime":"2025-02-19 22:09","pubTimestamp":1739974140,"startTime":"0","endTime":"0","summary":"This milestone builds on Clarity's earlier receipt of 2 FTDs for the diagnostic 64Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for initial definitive therapy[1], as well as patients with biochemical recurrence  of prostate cancer following definitive therapy[2], with 2 Phase III registration trials underway . These 3 FTDs demonstrate the quality of the data generated to date on the 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA products in addressing serious unmet needs in prostate cancer. The FTDs will enable Clarity to accelerate the development of its comprehensive program with the optimised SAR-bisPSMA agent to be used in patients with prostate cancer throughout the management of their cancer, from initial to late-stage disease, with an opportunity to completely change the entire treatment landscape for the large prostate cancer market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-receives-us-fda-fast-140900114.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-receives-us-fda-fast-140900114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["SAR","BK4213","BK4567","FAST","CU6.AU","BK4217","TGA","BK4084","PSA","BK4588","IE00BFXG0V08.USD","BK4104","BK7001","BCR","IE00B5TLWC47.USD","BK4585","BK4533","TGA.AU","SAR.AU","BK4135","IE00BYQQ9H92.USD","BK7096"],"gpt_icon":0},{"id":"2512476511","title":"2 ASX 200 pharmaceutical shares surging on big US news","url":"https://stock-news.laohu8.com/highlight/detail?id=2512476511","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512476511?lang=en_us&edition=fundamental","pubTime":"2025-02-19 12:02","pubTimestamp":1739937730,"startTime":"0","endTime":"0","summary":"The market may be heading lower today but that hasn't stopped two ASX 200 pharmaceutical shares from charging higher. Let's find out what big news out of the United States is giving them a big boost t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/19/2-asx-200-pharmaceutical-shares-surging-on-big-us-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","BK7508","NEU.AU","CU6.AU","BCR"],"gpt_icon":1},{"id":"2512449149","title":"Clarity Pharmaceuticals Secures US FDA Fast Track Designation for Prostate Cancer Drug Candidate; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512449149","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512449149?lang=en_us&edition=fundamental","pubTime":"2025-02-19 11:07","pubTimestamp":1739934466,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  received a fast track designation from the US Food and Drug Administration for its imaging agent Copper-67-SAR-bisPSMA for the potential treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have been previously treated with androgen receptor pathway inhibition, according to a Wednesday Australian bourse filing.Clarity earlier received two fast track designations for the diagnostic Copper-64-SAR-bisPSMA in prostate cancer patients.The designation was granted based on the preliminary results to date from the phase 1 and 2a study, which is investigating the safety and efficacy of copper-67-SAR-bisPSMA for the treatment of prostate cancer patients.It will allow for a faster review process once Clarity submits its product approval applications, per the filing.The trial is currently advancing through the highest dose group where participants were administered multiple doses of 12 gigabecquere","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BFXG0V08.USD","BK4567","CU6.AU","IE00BYQQ9H92.USD","IE00B5TLWC47.USD","BK4585","FAST","BK4104","BK4588","BK7096"],"gpt_icon":0},{"id":"2512486231","title":"Another win for Clarity at FDA as imaging agent fast-tracked for complex prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2512486231","media":"The Market Herald","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512486231?lang=en_us&edition=fundamental","pubTime":"2025-02-19 09:53","pubTimestamp":1739929980,"startTime":"0","endTime":"0","summary":"For those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity Pharmaceuticals’  news on Wednesday morning could offer crucial moral support.For those patients  Clarity’s imaging agent has been approved by the FDA for a fast-track study on that cohort.While Clarity doesn’t necessarily make drugs that actually attempt to ‘cure’ or mitigate cancer – rather image them in the human body using PET scans – those same drugs can have therapeutic effects on actual cancers too, given their radioactive nature.Clarity’s ultimate value proposition is its imaging agent is better than existing dominant products, meaning more cancerous growths can be revealed in a PET scan that other imaging agents might not enable for detection.That said, if the company can get rid of cancers too, well hey, even better.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/another-win-for-clarity-at-fda-as-imaging-agent-fast-tracked-for-complex-prostate-cancer-2025-02-19/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2512110446","title":"BRIEF-Clarity Pharmaceuticals Gets US FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2512110446","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512110446?lang=en_us&edition=fundamental","pubTime":"2025-02-19 09:36","pubTimestamp":1739929015,"startTime":"0","endTime":"0","summary":"BRIEF-Clarity Pharmaceuticals Gets US FDA Fast Track Designation Feb 19 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX:GETS US FDA FAST TRACK DESIGNATION FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTSFurther company coverage: CU6.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nFWN3P91CO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2512113123","title":"Clarity Pharmaceuticals - Gets US FDA Fast Track Designation for Treatment of Metastatic Castration-Resistant Prostate Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2512113123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512113123?lang=en_us&edition=fundamental","pubTime":"2025-02-19 06:31","pubTimestamp":1739917911,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nFWN3P91CO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":83,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[]}}